A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Status: Recruiting
Phase:
Diagnosis: Solid Tumor/Phase I
NCT ID: NCT00585195
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 06-068
PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/hepatocyte growth factor receptor tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma kinase (called ALK) tyrosine kinase. This research study is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth daily.
Conducting Institutions:
Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital, Beth-Israel Deaconess Medical Center
Overall PI:
Bruce Dezube, MD,
Beth Israel Deaconess Medical Center
Site-responsible Investigators:
Geoffrey Shapiro, MD, PhD,
Dana-Farber Cancer Institute
Jeffrey Clark, MD,
Massachusetts General Hospital
Contacts:
Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100
Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060
Eligibility Criteria
Inclusion Criteria:
- Advanced malignancies (except leukemias), histologically proven at diagnosis which is
refractory to standard of care therapy, or for whom no standard of care therapy is
available
- Solid tumors must have measurable disease
- Adequate blood cell counts, kidney function, liver function and Eastern Cooperative
Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG
score of 2 may be allowed on a case-by-case basis)
Exclusion Criteria:
- Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of
starting study treatment, depending on the dose level
- Prior stem cell transplant except of patients with lymphoma or myeloma
- Active or unstable cardiac disease or heart attack within 12 months of starting study
treatment